Zimmer Biomet Holdings, Inc. $ZBH Stock Holdings Lowered by Heritage Investors Management Corp

Heritage Investors Management Corp cut its holdings in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 5.2% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 113,823 shares of the medical equipment provider’s stock after selling 6,235 shares during the period. Heritage Investors Management Corp owned approximately 0.06% of Zimmer Biomet worth $10,111,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. BlackRock Inc. bought a new stake in Zimmer Biomet during the second quarter valued at approximately $1,344,282,000. State Street Corp boosted its stake in shares of Zimmer Biomet by 0.6% during the 2nd quarter. State Street Corp now owns 8,877,171 shares of the medical equipment provider’s stock worth $766,343,000 after acquiring an additional 52,044 shares during the last quarter. Primecap Management Co. CA bought a new stake in shares of Zimmer Biomet during the 2nd quarter valued at $328,578,000. Dimensional Fund Advisors LP increased its stake in shares of Zimmer Biomet by 1.1% in the 1st quarter. Dimensional Fund Advisors LP now owns 2,224,163 shares of the medical equipment provider’s stock worth $201,082,000 after purchasing an additional 24,208 shares in the last quarter. Finally, Bank of America Corp DE purchased a new stake in shares of Zimmer Biomet in the 2nd quarter worth $187,480,000. Hedge funds and other institutional investors own 88.89% of the company’s stock.

Insider Buying and Selling at Zimmer Biomet

In other Zimmer Biomet news, insider Chad F. Phipps sold 3,000 shares of the business’s stock in a transaction on Friday, September 4th. The shares were sold at an average price of $98.35, for a total value of $295,050.00. Following the sale, the insider owned 65,231 shares in the company, valued at $6,415,468.85. The trade was a 4.40% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Kevin R. Thornal sold 5,691 shares of the stock in a transaction dated Friday, September 11th. The shares were sold at an average price of $92.95, for a total transaction of $528,978.45. The SEC filing for this sale provides additional information. Company insiders own 1.28% of the company’s stock.

Zimmer Biomet Stock Up 0.0%

NYSE ZBH opened at $94.54 on Monday. Zimmer Biomet Holdings, Inc. has a 12 month low of $79.12 and a 12 month high of $103.70. The company has a current ratio of 1.69, a quick ratio of 0.94 and a debt-to-equity ratio of 0.50. The stock has a market cap of $18.03 billion, a PE ratio of 23.00, a P/E/G ratio of 2.27 and a beta of 0.49. The stock’s 50 day moving average is $94.86 and its 200 day moving average is $91.70.

Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings data on Wednesday, August 5th. The medical equipment provider reported $2.07 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.01 by $0.06. The business had revenue of $2.18 billion during the quarter, compared to analyst estimates of $2.13 billion. Zimmer Biomet had a net margin of 9.48% and a return on equity of 13.12%. The company’s revenue was up 4.8% on a year-over-year basis. During the same period last year, the firm posted $2.07 EPS. Zimmer Biomet has set its FY 2026 guidance at 8.470-8.590 EPS. Research analysts predict that Zimmer Biomet Holdings, Inc. will post 8.54 EPS for the current fiscal year.

Zimmer Biomet Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, October 30th. Investors of record on Wednesday, September 30th were paid a dividend of $0.24 per share. This represents a $0.96 annualized dividend and a yield of 1.0%. The ex-dividend date of this dividend was Wednesday, September 30th. Zimmer Biomet’s dividend payout ratio (DPR) is presently 23.36%.

Analysts Set New Price Targets

Several equities analysts recently weighed in on the company. UBS Group reiterated a “buy” rating and set a $120.00 target price on shares of Zimmer Biomet in a research report on Thursday, August 6th. Zacks Research upgraded Zimmer Biomet from a “strong sell” rating to a “hold” rating in a research report on Tuesday, August 25th. Truist Financial raised their price objective on Zimmer Biomet from $92.00 to $106.00 and gave the stock a “hold” rating in a research note on Thursday, August 6th. Royal Bank Of Canada boosted their price objective on Zimmer Biomet from $101.00 to $110.00 and gave the company an “outperform” rating in a research note on Thursday, August 6th. Finally, Wall Street Zen upgraded Zimmer Biomet from a “hold” rating to a “buy” rating in a research note on Saturday. Seven investment analysts have rated the stock with a Buy rating, fifteen have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $104.47.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc is a medical technology company that develops and manufactures products used in orthopedic surgery and musculoskeletal care. Its portfolio includes implants for the hip, knee, shoulder, and other joints, as well as products for sports medicine, extremity reconstruction, trauma, and spine procedures.

The company also offers surgical technologies and solutions designed to support orthopedic procedures, including robotic-assisted surgery systems, digital tools, patient-specific planning, and related instruments.